{"entity":{"id":"nct06244771","kind":"trial","name":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of FMC-376 in non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, run by Frontier Medicines Corporation, now recruiting.","summary":"A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors is a phase 1/2 interventional study registered as NCT06244771 by Frontier Medicines Corporation, with 403 participants planned, started 2024-02-12 and due to reach its primary completion in 2027-10. Interventions recorded: FMC-376.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06244771","url":"https://clinicaltrials.gov/study/NCT06244771"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","colorectal","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["frontier-medicines"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06244771","phase":"1/2","setting":"An Open-Label, Phase 1/2 Dose Escalation, Dose Expansion and Cohort Expansion Study Evaluating the Safety, PK and Clinical Activity of FMC-376 in Participants With KRAS G12C Mutated Locally Advanced Unresectable or Metastatic Solid Tumors","sponsor":"Frontier Medicines Corporation","enrolled":403,"outcomes":[]},"route":"/trials/nct06244771/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"company":[{"id":"frontier-medicines","kind":"company","name":"Frontier Medicines","route":"/companies/frontier-medicines/"}]}}